New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous ...

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, ...

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample ...

A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

Panelist discusses how genetic testing is recommended for all patients with pancreatic adenocarcinoma at diagnosis, including ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...